

MCKOOL SMITH, PC
John J. Sparacino (TX Bar No. 18873700)
S. Margie Venus (TX Bar No. 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile: (713) 485-7344
Email: jsparacino@mckoolsmith.com
Email: mvenus@mckoolsmith.com

PORZIO, BROMBERG & NEWMAN, P.C.
Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
100 Southgate Parkway
P.O. Box 1997
Morristown, New Jersey 07962-1997
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
Email: WJMartin@pbnlaw.com
Email: RAParisi@pbnlaw.com

Travis E. DeArman (TX Bar No. 24074117)
300 Crescent Court, Suite 1200
Dallas, Texas 75201
Telephone: (214) 978-4000
Facsimile: (214) 978-4044
Email: tdearman@mckoolsmith.com

*Counsel for the Liquidating Trustee, Dundon
Advisers LLC*

**IN THE UNITED STATES BANKRUPTCY COURT
NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION**

In re:	§	Chapter 11
EIGER BIOPHARMACEUTICALS, INC.,	§	Case No. 24-80040 (SGJ)
<i>et al.</i> , ¹	§	
Debtors.	§	(Jointly Administered)

**THE LIQUIDATING TRUSTEE’S
AMENDED
AGENDA FOR HEARING SCHEDULED FOR
APRIL 15, 2025 AT 9:30 A.M. (PREVAILING CENTRAL TIME)**

Dundon Advisers, LLC, c/o Joshua Nahas, in its capacity as liquidating trustee (the “Liquidating Trustee”) of the liquidating trust of Eiger BioPharmaceuticals, Inc., et al. (the “Liquidating Trust”), by and through its undersigned counsel, in the above-captioned Chapter 11

¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Ave., Dallas, Texas 75201.



bankruptcy proceedings of the above-captioned post-effective date debtors and debtors-in-possession (the “Debtors”), files this agenda for hearing scheduled on ***April 15, 2025 at 9:30 a.m. (Prevailing Central Time)***, before the Honorable Stacey G. C. Jernigan at the United States Bankruptcy Court for the Northern District of Texas, Courtroom #1, 14th Floor, Earle Cabell Federal Building, 1100 Commerce Street, Suite 1254, Dallas, Texas 75242:

AGENDA MATTER

1. *The Liquidating Trustee’s and Plan Administrator’s Objection to Claims Nos. 83 and 43 Filed by Merck Sharp and Dohme LLC* [Docket No. 771 (redacted); Docket No. 774 (sealed)]

Related Documents:

- a. Liquidating Trustee’s Emergency Motion for Entry of an Order Authorizing the Filing of (I) the Liquidating Trustee’s and Plan Administrator’s Objection to Claim Nos. 83 and 43 Filed by Merck Sharp and Dohme LLC (II) Merck License, and (III) Side Letter Under Seal [Docket No. 770]
- b. *Declaration of Joshua Nahas in Support of the Liquidating Trustee’s and Plan Administrator’s Objection to Claim Nos. 83 and 43 Filed by Merck Sharp and Dohme LLC* [Docket No. 772 (redacted); Docket No. 775 (sealed)]
- c. *Order Authorizing the Liquidating Trustee to File (I) the Liquidating Trustee’s and Plan Administrator’s Objection to Claim Nos. 83 and 43 Filed by Merck Sharp and Dohme LLC, (II) Merck License, and (III) Side Letter Under Seal* [Docket No. 773].
- d. *Notice of Hearing for April 15, 2025 Setting* [Docket No. 786]
- e. *The Liquidating Trustee’s Witness and Exhibit List for April 15, 2025 Hearing* [Docket No. 806]

Status: The matter has been settled.

2. *EIT Pharma, Inc., Formerly Known as Eiger InnoTherapeutics, Inc.’s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 787]

Related Documents:

- a. *Sentynl Therapeutics, Inc.’s (I) Response to EIT Pharma, Inc., Formerly Known as Eiger InnoTherapeutics, Inc.’s Emergency Motion to Confirm terms of Lonafarnib/Lambda Sale Order and (II) Request for Status Conference Pursuant to 11 U.S.C. § 105(d)* [Docket No. 790]

- b. *Notice of Hearing on EIT Pharma, Inc., Formerly Known as Eiger InnoTherapeutics, Inc.'s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 792]
- c. *The Liquidating Trustee's Witness and Exhibit List for April 15, 2025 Hearing* [Docket No. 806]
- d. *Witness and Exhibit List for April 15, 2025 Hearing on EIT Pharma, Inc.'s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 807]
- e. *EIT Pharma, Inc.'s Witness and Exhibit List for April 15 Hearing on Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 808]
- f. *Sentynl Therapeutics, Inc.'s Supplemental Response and Objection to EIT Pharma, Inc., Formerly Known as Eiger InnoTherapeutics, Inc.'s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 809 (sealed); Docket No. 810 (redacted)]
- g. *Notice of Filing of Corrected Exhibit to EIT Pharma, Inc.'s Witness and Exhibit List for April 15, 2025, Hearing on Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 814]
- h. *EIT Pharma, Inc.'s, Reply in Support of Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order* [Docket No. 816]

Status: This matter is contested and going forward.

- 3. Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc. [Docket No. 777 (redacted); Docket No. 784 (sealed)]

Related Documents:

- a. *Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutic, Inc.* [Docket No. 729]
- b. *Liquidating Trustee's Emergency Motion for Entry of an Order Authorizing the Filing of (I) the Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc., and (II) Declaration and Declaration Exhibits in Support of the Objection and Response Under Seal* [Docket No. 776]
- c. *Declaration of Joshua Nahas in Support of Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc. (redacted)* [Docket No. 778 (redacted); Docket No. 785 (sealed)]

- d. *Order Authorizing the Liquidating Trustee to File (I) the Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc., and (II) Declaration and Declaration Exhibits in Support of the Objection and Response Under Seal* [Docket No. 783]
- e. *Notice of Hearing for April 15, 2025 Setting* [Docket No. 786]
- f. *Sentynl Therapeutics Inc.'s Omnibus Emergency Motion for Entry of an Order (I) Setting Status Conference and Continuing Evidentiary Hearing; (II) Authorizing Additional Pages for Sentynl's Reply Brief in Support of its Motion for Allowance; and (III) Authorizing Sentynl to File its Reply Brief in Support of its Motion for Allowance and Supporting Exhibits Under Seal* [Docket No.797]
- g. *Response of the Liquidating Trustee to Emergency Motion of Sentynl Therapeutics, Inc. for Entry of an Order (I) Setting Status Conference and Continuing Evidentiary Hearing; (II) Authorizing Additional Pages for Sentynl's Reply Brief in Support of its Motion for Allowance; and (III) Authorizing Sentynl to File its Reply Brief in Support* [Docket No. 799 (redacted); Docket No. 798 (sealed)]
- h. *Reply in Support of Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc.* [Docket No. 800 (redacted); Docket No. 801 (sealed)]
- i. *Order (I) Setting Status Conference and Continuing Evidentiary Hearing; (II) Authorizing Additional Pages for Sentynl's Reply Brief in Support of its Motion for Allowance; and (III) Authorizing Sentynl to File its Reply Brief in Support of its Motion for Allowance and Supporting Exhibits Under Seal* [Docket No. 802]
- j. *Notice of Status Conference* [Docket No. 804]
- k. *The Liquidating Trustee's Witness and Exhibit List for April 15, 2025 Hearing* [Docket No. 806]

Status: This matter is contested and going forward as a status conference.

- 4. *Sentynl Therapeutics, Inc.'s Motion (I) to Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 779]

Related Documents:

- a. *Appendix in Support of Sentynl Therapeutics, Inc's Motion (I) to Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 780]
- b. *Sentynl Therapeutics, Inc.'s Motion (I) to Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 781]

- c. *Appendix in Support of Sentynl Therapeutics, Inc.’s Motion (I) to Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 782]
- d. *Notice of Hearing for April 15, 2025 Setting* [Docket No. 786]
- e. *Limited Response of the Liquidating Trustee and Plan Administrator to Motion of Sentynl Therapeutics, Inc. to (I) Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 793 (sealed); Docket No. 794 (redacted)]
- f. *Declaration of James Vollins in Support of the Liquidating Trustee and the Plan Administrator’s Limited Response to Motion of Sentynl Therapeutics, Inc. to (I) Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 795]
- g. *Joint Stipulation and Agreed Order* [Docket No. 796]
- h. *Joint Stipulation and Agreed Order* [Docket No. 803] entered April 9, 2025
- i. *Notice of Status Conference* [Docket No. 805]
- j. *The Liquidating Trustee’s Witness and Exhibit List for April 15, 2025 Hearing* [Docket No. 806]
- k. *EIT Pharma, Inc’s Response to Motion of entynl Therapeutics, Inc. to (I) Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger InnoTherapeutics, Inc.* [Docket No. 812]

Status: This matter is contested and going forward as a status conference.

[Remainder of page intentionally left blank.]

Dated: April 14, 2025

Respectfully submitted,

MCKOOL SMITH, PC

/s/ S. Margie Venus

John J. Sparacino (SBN 18873700)
S. Margie Venus (SBN 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile (713) 485-7344
jsparacino@mckoolsmith.com
mvenus@mckoolsmith.com

Travis E. DeArman (SBN 24074117)
300 Crescent Court, Suite 1200
Dallas, Texas 75201
Telephone (214) 978-4000
Facsimile (214) 978-4044
tdearman@mckoolsmith.com

-and-

Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
PORZIO, BROMBERG & NEWMAN, P.C.
100 Southgate Parkway
P.O. Box 1997
Morristown, New Jersey 07962-1997
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
WJMartin@pbnlaw.com
RAParisi@pbnlaw.com

*Counsel for the Liquidating Trustee,
Dundon Advisers LLC*

CERTIFICATE OF SERVICE

I certify that on April 14, 2025, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas.

/s/ S. Margie Venus
S. Margie Venus